By Padmanabhan Ananthan June 18 (Reuters) - Pfizer said on Thursday that finance chief Dave Denton will leave on August 15 to ...

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...

Learn more Dave Denton, Pfizer's chief financial officer, is departing the pharmaceutical company for a position in consumer ...

Pfizer's business may be in better shape than investors think.

Pfizer is rated a Buy with 55%+ upside potential, driven by a robust pipeline and undervalued forward earnings. Read more on ...

Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the ...

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts ...

Pfizer (PFE) stock drops 3% as CFO Dave Denton reveals August exit. Cecile Guegan appointed interim CFO while company ...

The UK competition watchdog has won permission to appeal in a case against US pharmaceutical giant Pfizer after a ...

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight ...

Congenital syphilis should be preventable. An Arizona case shows how drug shortages and procedural hurdles are fueling a ...

The biotech company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry ...